- The latest circVec 3.0 generation of its circular RNA therapeutic platform technology has now been validated in multiple vector formats
- New delivery data demonstrates efficient delivery to the spleen, opening novel circVec opportunities in cell therapy
- Rich pipeline of upcoming R&D milestones, including several existing and new research collaborations
- Presentation of 2024 financial results, including ongoing activities to strengthen Circio´s financial position
Oslo, Norway 26 March 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, is hosting a live webcast at 10:00am CET today Wednesday 26 March 2025. In the webcast, Circio management will present the 2024 financial results, provide a general corporate update and present the latest developments for the circVec platform technology.
The presentation will show the advantages and potential of Circio’s newest circVec 3.0 generation and ongoing activities to validate its performance in therapeutic vector formats. In addition, recent systemic LNP-delivery data will be discussed that demonstrate robust and durable circVec expression in the spleen, far outperforming equivalent mRNA-vectors. This important finding creates potential therapeutic opportunities for the circVec technology in new areas, such as cell therapy.
“Circio’s latest results showing efficient and specific LNP-delivery to the spleen are very promising and have the potential to open up novel opportunities for the circVec platform in cell and immune therapies,” said Dr. Erik D Wiklund, CEO of Circio. “We now have a broad set of ongoing experiments, both internally and through several external research collaborations, that are generating multiple important in vivo data read outs during Q2. The performance of circVec 3.0-AAV constructs is of particular importance, with the potential to generate substantial near-term partnering interest.”
A summary of the financial results for 2024 and corporate outlook for 2025 will also be covered in the presentation. During 2024, Circio completed both a rights issue and private placement, strengthening the financial situation and shareholder base of the company. In parallel, substantial cost saving measures were implemented, thereby extending the cash runway and enabling maximized R&D progress on a low cost base. A multi-pronged strategy is being pursued to secure long-term funding, including extension of the Atlas financing commitment, fundraising and structural and business development transactions.
Presenters:
CEO Dr. Erik Digman Wiklund
CFO Dr. Lubor Gaal
Time: 10:00 CET on 26 March 2025
click here to access the Teams webcast
Meeting ID: 392 868 593 190
Passcode: Mn7uS2qQ
Participate by phone:
+47 21402155
Phone conference ID: 394 288 903#
A recording of the webcast will be made available on the Circio webpage
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com
About Circio
Building next generation RNA technology for nucleic acid medicine
Circio Holding ASA is a biotechnology company developing powerful circular RNA vector expression technology for next generation nucleic acid medicine.
Circio has established a unique circular RNA (circRNA) vector expression platform for novel DNA, RNA and viral therapeutics. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA inside cells, which can be deployed in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. The circVec platform has demonstrated up to 15-fold enhanced and more significantly more durable protein expression vs. classic mRNA vector systems and has the potential to become a new gold-standard platform technology for nucleic acid and viral therapeutics in the future. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB based at the Karolinska Institute in Stockholm, Sweden.
In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS driver mutations. TG01 is currently being tested in two clinical trials: RAS-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway. These studies are being run through academic and industry collaborative networks, supported by prestigious research grants from Innovation Norway and the Norwegian Research Council, creating read-outs and future optionality for the program at low cost to Circio.
This information is considered to be inside information pursuant to the EU Market Abuse Regulation (MAR) and is subject to the disclosure requirements pursuant to MAR article 17 and section 5-12 of the Norwegian Securities Trading Act.
This stock exchange announcement was published by Erik Digman Wiklund, CEO, on behalf of the Company, at the time and date stated above in this announcement.